№52 / М. Парфенова

Литература

  1. Tan J, ROSCO co authors. Updating the diagnosis, classification and assessment of rosacea by effacement of subtypes: reply from the author. Br J Dermatol, 2017, Aug, № 177(2). PP. 598-599. 
  2. Tan J, Schofer H, Araviiskaia E, Audibert F, Kerrouche N, Berg M. Prevalence of rosacea in the general population of Germany and Russia – the RISE study. JEADV, 2016, Mar, № 30(3). PP. 428-34.
  3. Elewsky B, Draelos Z, Dreno B. Rosacea – global diversity and optimized outcome: proposed international consensus from the Rosacea International Expert Group. JEADV, 2011, № 25. PP. 188-200.
  4. Crawford GH, Pelle MT, James WD. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol, 2004, Sep, № 51(3). PP. 327-41.
  5. Ашапкин В., Кутуева Л., Волкова Е., Ванюшин Б. Экспериментальное обоснование механизмов действия MesoEye С71: влияние на состояние кровеносных сосудов // Les nouvelles esthetiques, 2016, № 4. 
  6. Buddenkotte J, Steinhoff M. Recent advances in understanding and managing rosacea. F1000Res, 2018, № 7. P. 1885.
  7. Труфанов С. В., Шахбазян Н. П. Офтальморозацеа: этиопатогенез и современные методы лечения // Вестник офтальмологии, 2018, № 134(3). С. 121128.
  8. Oltz M, Check J. Rosacea and its ocular manifestations. Optometry — Journal of the American Optometric Association, 2011, № 82(2). PP. 92-103.
  9. Awais M, Anwar MI, Iftikhar R, Iqbal Z, Shehzad N, Akbar B. Rosacea — the ophthalmic perspective. Cutaneous and ocular toxicology, 2015, № 34(2). PP. 161- 166. 
  10. Webster GF, Durrani K, Suchecki J. Ocular rosacea, psoriasis, and lichen planus. Clinics in dermatology, 2016, № 34(2). PP. 146-150. 
  11. Quarterman MJ, Johnson DW, Abele DC, Lesher JL, Hull DS, Davis LS. Ocular rosacea: signs, symptoms, and tear studies before and after treatment with doxycycline. Archives of dermatology, 1997, № 133(1). PP. 49-54.